ReviewThe Korean journal of internal medicine2020
Recent advances in diagnostic technologies in lung cancer.
Review in The Korean journal of internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Atrial resection for T4 non-small cell lung cancer with left atrium involvement: a systematic review and meta-analysis of survival.Surgery today · 2023Pooled it
- Retrospective Evaluation of Safety of Using a Semi-automatic Robotic System for Transthoracic Biopsy of Lung Mass Under Positron Emission Tomography-computed Tomography Guidance.Thoracic research and practice · 2026Article
- Blood-Based miRNA Panels for Timely Detection of Non-Small-Cell Lung Cancer: From Biomarker Discovery to Clinical Translation.International journal of molecular sciences · 2025Review
- Observational
- Advancements in Imaging Technologies for the Diagnosis of Lung Cancer and Other Pulmonary Diseases.Diagnostics (Basel, Switzerland) · 2025Review
- Exploring the Role of Vitamin D, Vitamin D-Dependent Proteins, and Vitamin D Receptor Gene Variation in Lung Cancer Risk.International journal of molecular sciences · 2024Review
- Advancements and Challenges in the Image-Based Diagnosis of Lung and Colon Cancer: A Comprehensive Review.Cancer informatics · 2024Review
- Impact of AI-assisted CXR analysis in detecting incidental lung nodules and lung cancers in non-respiratory outpatient clinics.Frontiers in medicine · 2024Article
- Application of target scanning combined with three-dimensional reconstruction in the diagnosis of early-stage lung adenocarcinoma.Journal of Cancer · 2024Article
- Liquid biopsy for assessment of RFS (recurrence-free survival) in NSCLC (non-small cell lung cancer) patients post-treatment through circulating tumour DNA detection: A meta-analysis.The journal of liquid biopsy · 2023Review
- Article
- LINC01117 inhibits invasion and migration of lung adenocarcinoma through influencing EMT process.PloS one · 2023Article
- Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma.Mediators of inflammation · 2023Article
- Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer.Diagnostics (Basel, Switzerland) · 2022Review
- Recent Trends of Lung Cancer in Korea.Tuberculosis and respiratory diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increase in lung cancer incidence of Korea has been dampened since 2000; however, increased human lifespan, interest in health care and the widespread implementation of health examinations have resulted in a considerable rise in detection of small lesions that need to be differentiated from lung cancer. Detection of lung cancer at an early stage rather than at a symptomatic advanced stage is also increasing, suggesting that there are increasing diagnostic demands for small peripheral lung lesions. The development of new molecular diagnostics, including next generation sequencing, companion diagnostics that accompany development of new anti-cancer drugs, and re-biopsy for application of new therapeutic modality accelerate the development of lung cancer diagnostics. In this review, we extensively describe the current available diagnostic tools in lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.